Exosomes obtained from human adipose-derived stem cells alleviate epileptogenesis in the pentylenetetrazol model of epilepsy.

IF 1.6 4区医学 Q4 NEUROSCIENCES

Neuroreport Pub Date : 2025-02-05 Epub Date: 2025-01-29 DOI:10.1097/WNR.0000000000002133

Fateme Derisfard, Zahra Jafarinezhad, Negar Azarpira, Mohammad Reza Namavar, Hadi Aligholi

{"title":"Exosomes obtained from human adipose-derived stem cells alleviate epileptogenesis in the pentylenetetrazol model of epilepsy.","authors":"Fateme Derisfard, Zahra Jafarinezhad, Negar Azarpira, Mohammad Reza Namavar, Hadi Aligholi","doi":"10.1097/WNR.0000000000002133","DOIUrl":null,"url":null,"abstract":"<p><p>As exosome therapy is a promising treatment in neurological disorders including epilepsy, the present study aimed to evaluate the effects of exosomes obtained from human adipose-derived stem cells (ADSCs) on pentylenetetrazol (PTZ) model of epilepsy in mice. Thirty adult mice were divided into PTZ, diazepam + PTZ, and exosome (5, 10, and 15 µg) + PTZ groups. The exosomes were administered intranasally 30 min before PTZ injection. The seizure latency, tonic-clonic onset, seizure duration, and mortality protection rate were monitored. Also, the level of hippocampal malondialdehyde (MDA), the oxidative stress marker, was evaluated. Exosomes in 5 and 15 µg concentration significantly increased seizure latency. Only 15 µg of exosomes induced a considerable delay in tonic-clonic onset. Seizure duration was significantly attenuated in the 5 µg exosome group. In addition, the 5-µg exosome indicated the highest mortality protection rate. Furthermore, the MDA level was significantly reduced in all animals treated by exosomes. Exosomes obtained from human ADSCs could alleviate epileptogenesis induced by PTZ maybe through reducing hippocampal oxidative stress.</p>","PeriodicalId":19213,"journal":{"name":"Neuroreport","volume":"36 3","pages":"161-168"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroreport","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNR.0000000000002133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

As exosome therapy is a promising treatment in neurological disorders including epilepsy, the present study aimed to evaluate the effects of exosomes obtained from human adipose-derived stem cells (ADSCs) on pentylenetetrazol (PTZ) model of epilepsy in mice. Thirty adult mice were divided into PTZ, diazepam + PTZ, and exosome (5, 10, and 15 µg) + PTZ groups. The exosomes were administered intranasally 30 min before PTZ injection. The seizure latency, tonic-clonic onset, seizure duration, and mortality protection rate were monitored. Also, the level of hippocampal malondialdehyde (MDA), the oxidative stress marker, was evaluated. Exosomes in 5 and 15 µg concentration significantly increased seizure latency. Only 15 µg of exosomes induced a considerable delay in tonic-clonic onset. Seizure duration was significantly attenuated in the 5 µg exosome group. In addition, the 5-µg exosome indicated the highest mortality protection rate. Furthermore, the MDA level was significantly reduced in all animals treated by exosomes. Exosomes obtained from human ADSCs could alleviate epileptogenesis induced by PTZ maybe through reducing hippocampal oxidative stress.

查看原文本刊更多论文

从人脂肪来源的干细胞中获得的外泌体减轻戊四氮唑癫痫模型的癫痫发生。

鉴于外泌体疗法在包括癫痫在内的神经系统疾病中是一种很有前景的治疗方法，本研究旨在评估从人脂肪源性干细胞（ADSCs）中获得的外泌体对小鼠戊四氮唑（PTZ）癫痫模型的影响。将30只成年小鼠分为PTZ、地西泮+ PTZ和外泌体（5、10和15µg） + PTZ组。外泌体在PTZ注射前30分钟经鼻给药。监测发作潜伏期、强直阵挛发作、发作持续时间和死亡率保护率。此外，我们还评估了氧化应激标志物海马丙二醛（MDA）的水平。5µg和15µg浓度的外泌体显著增加癫痫发作潜伏期。仅15µg外泌体可显著延缓强直-阵挛发作。5µg外泌体组癫痫发作时间明显缩短。此外，5µg外泌体显示出最高的死亡保护率。此外，外泌体处理的所有动物的MDA水平均显著降低。从人ADSCs中获得的外泌体可能通过降低海马氧化应激来减轻PTZ诱导的癫痫发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroreport 医学-神经科学

CiteScore

3.20

自引率

0.00%

发文量

150

审稿时长

1 months

期刊介绍： NeuroReport is a channel for rapid communication of new findings in neuroscience. It is a forum for the publication of short but complete reports of important studies that require very fast publication. Papers are accepted on the basis of the novelty of their finding, on their significance for neuroscience and on a clear need for rapid publication. Preliminary communications are not suitable for the Journal. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool. The core interest of the Journal is on studies that cast light on how the brain (and the whole of the nervous system) works. We aim to give authors a decision on their submission within 2-5 weeks, and all accepted articles appear in the next issue to press.